Dr Emily Sammons
Contact information
Emily Sammons
BSc, MBChB, MSc
Clinical Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), with particular research interests in diabetic eye disease and age-related macular degeneration.
Alongside this, she works on two large randomised controlled trials: ASCEND and REVEAL.
ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes.
REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease.
Emily has background experience of working in General Medicine and a MSc in Public Health.
Recent publications
-
Experience of Linking to the NHS Diabetic Eye Screening Programme Records in the ASCEND-Eye Randomized Trial and Recommendations for Improvement
Journal article
SAMMONS E., (2025), Contemporary Clinical Trials Communications
-
The Effects of Aspirin and Omega-3 Fatty Acids on Age-Related Macular Degeneration in ASCEND-Eye, A Randomised Placebo Controlled Trial in a Population with Diabetes
Journal article
SAMMONS E., (2025), BMJ Open
-
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Journal article
Judge PK. et al, (2024), Nephrol Dial Transplant
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
-
Effects of Aspirin and Omega-3 Fatty Acids on Composite and Subdomain Scores from the NEI-VFQ-25 Questionnaire: The ASCEND-Eye Randomized Controlled Trial
Journal article
SAMMONS E. et al, (2024), BMC Ophthalmology